Literature DB >> 26405677

Leptin expression in HIV-infected patients during antiretroviral therapy.

Cătălin Tiliscan1, Victoria Aramă1, Raluca Mihăilescu2, Daniela Ioana Munteanu3, Adrian Streinu-Cercel1, Daniela Adriana Ion4, Mihaela Andreea Rădulescu1, Cristina Popescu1, Alina Elena Lobodan5, Anca Ruxandra Negru5, Ştefan Sorin Aramă4.   

Abstract

BACKGROUND: Leptin is an adipokine with complex metabolic, neuroendocrine and immune functions. Our objective was to evaluate leptin serum levels in a cohort of Romanian HIV-infected patients undergoing antiretroviral therapy in relation to their immune-virological status, lipid and glucose metabolic abnormalities and the presence of metabolic syndrome (MS).
METHODS: We enrolled consecutive non-diabetic HIV-infected patients aged 18 and over on stable cART for at least 6 months. Blood samples were tested for: leptin, CD4 T cells count, HIV viral load and lipid panel.
RESULTS: A total of 90 HIV-infected patients were included in the study: 50 males (55.6%) with a mean age of 33.3 years and 40 females with a mean age of 30.4 years. Most patients (74.4%) had HIV viral load below the limit of detection and the median CD4 count for the cohort was 476 (410) cells/cmm. More than one third of the patients (41.1%) had hypoleptinemia. The prevalence of MS was 13.3%. Hypoleptinemia was significantly more frequent in men. In a subset of patients with undetectable HIV viral load, the median leptin value was 0.6 (6.07) ng/mL in patients with poor immune recovery (CD4 count ≤ 200/cmm) compared to 2 (3.07) ng/mL for those with better immune response (CD4 count > 200/cmm), without statistical significance. The median values of leptin were similar for persons with and without MS criteria. HDL-cholesterol values were positively correlated to leptin values in a linear regression model.
CONCLUSION: A significant proportion of patients in our study presented low levels of leptin; this finding was not associated with immune and virological parameters or the presence of MS. Hypoleptinemia was significantly correlated with lower levels of HDL-cholesterol, a key cardiovascular risk factor.

Entities:  

Keywords:  HDL-cholesterol; HIV; Leptin; antiretroviral therapy

Year:  2015        PMID: 26405677      PMCID: PMC4570839          DOI: 10.11599/germs.2015.1076

Source DB:  PubMed          Journal:  Germs        ISSN: 2248-2997


  18 in total

1.  Leptin and HDL-cholesterol in non-diabetic normotensive subjects.

Authors:  G M Marinari; N Scopinaro; G F Adami
Journal:  Obes Surg       Date:  2001-06       Impact factor: 4.129

Review 2.  Management of fat accumulation in patients with HIV infection.

Authors:  Julian Falutz
Journal:  Curr HIV/AIDS Rep       Date:  2011-09       Impact factor: 5.071

Review 3.  The role of leptin/adiponectin ratio in metabolic syndrome and diabetes.

Authors:  Patricio López-Jaramillo; Diego Gómez-Arbeláez; Jose López-López; Cristina López-López; Javier Martínez-Ortega; Andrea Gómez-Rodríguez; Stefany Triana-Cubillos
Journal:  Horm Mol Biol Clin Investig       Date:  2014-04

Review 4.  Leptin in human physiology and pathophysiology.

Authors:  Christos S Mantzoros; Faidon Magkos; Mary Brinkoetter; Elizabeth Sienkiewicz; Tina A Dardeno; Sang-Yong Kim; Ole-Petter R Hamnvik; Anastasia Koniaris
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-07-26       Impact factor: 4.310

5.  Metabolic syndrome defined by modified International Diabetes Federation criteria and type 2 diabetes mellitus risk: a 9-year follow-up among the aged in Finland.

Authors:  Marika Salminen; Marikka Kuoppamäki; Tero Vahlberg; Ismo Räihä; Kerttu Irjala; Sirkka-Liisa Kivelä
Journal:  Diab Vasc Dis Res       Date:  2012-03-29       Impact factor: 3.291

6.  Positional cloning of the mouse obese gene and its human homologue.

Authors:  Y Zhang; R Proenca; M Maffei; M Barone; L Leopold; J M Friedman
Journal:  Nature       Date:  1994-12-01       Impact factor: 49.962

Review 7.  Update on metabolic issues in HIV patients.

Authors:  Marta Calvo; Esteban Martinez
Journal:  Curr Opin HIV AIDS       Date:  2014-07       Impact factor: 4.283

Review 8.  Central leptin insufficiency syndrome: an interactive etiology for obesity, metabolic and neural diseases and for designing new therapeutic interventions.

Authors:  Satya P Kalra
Journal:  Peptides       Date:  2007-10-24       Impact factor: 3.750

9.  Leptin in relation to the lipodystrophy-associated metabolic syndrome.

Authors:  Christos S Mantzoros
Journal:  Diabetes Metab J       Date:  2012-06-14       Impact factor: 5.376

Review 10.  Leptin as a novel therapeutic target for immune intervention.

Authors:  G Matarese; V Sanna; S Fontana; S Zappacosta
Journal:  Curr Drug Targets Inflamm Allergy       Date:  2002-03
View more
  5 in total

1.  Risk Factors for Weight Gain Following Switch to Integrase Inhibitor-Based Antiretroviral Therapy.

Authors:  Jordan E Lake; Kunling Wu; Sara H Bares; Paula Debroy; Catherine Godfrey; John R Koethe; Grace A McComsey; Frank J Palella; Katherine Tassiopoulos; Kristine M Erlandson
Journal:  Clin Infect Dis       Date:  2020-12-03       Impact factor: 9.079

Review 2.  Undernutrition and HIV Infection in Sub-Saharan Africa: Health Outcomes and Therapeutic Interventions.

Authors:  Hubaida Fuseini; Ben A Gyan; George B Kyei; Douglas C Heimburger; John R Koethe
Journal:  Curr HIV/AIDS Rep       Date:  2021-02-19       Impact factor: 5.071

3.  Effect of tuberculosis treatment on leptin levels, weight gain, and percentage body fat in Indonesian children.

Authors:  Maria Mexitalia; Yesi Oktavia Dewi; Adriyan Pramono; Mohammad Syarofil Anam
Journal:  Korean J Pediatr       Date:  2017-04-25

4.  Evaluation of Oral Antiretroviral Drugs in Mice With Metabolic and Neurologic Complications.

Authors:  Fuu-Jen Tsai; Mao-Wang Ho; Chih-Ho Lai; Chen-Hsing Chou; Ju-Pi Li; Chi-Fung Cheng; Yang-Chang Wu; Xiang Liu; Hsinyi Tsang; Ting-Hsu Lin; Chiu-Chu Liao; Shao-Mei Huang; Jung-Chun Lin; Chih-Chien Lin; Ching-Liang Hsieh; Wen-Miin Liang; Ying-Ju Lin
Journal:  Front Pharmacol       Date:  2018-09-04       Impact factor: 5.810

5.  HIV Protease Inhibitor Ritonavir Impairs Endothelial Function Via Reduction in Adipose Mass and Endothelial Leptin Receptor-Dependent Increases in NADPH Oxidase 1 (Nox1), C-C Chemokine Receptor Type 5 (CCR5), and Inflammation.

Authors:  Thiago Bruder-Nascimento; Taylor C Kress; Simone Kennard; Eric J Belin de Chantemèle
Journal:  J Am Heart Assoc       Date:  2020-10-02       Impact factor: 5.501

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.